✦ LIBER ✦

Treatment of liver metastases from uveal melanoma by combined surgery—chemotherapy

✍ Scribed by R.J. Salmon; C. Levy; C. Plancher; T. Dorval; L. Desjardins; S. Leyvrazi; P. Pouillart; P. Schlienger; V Servois; B. Asselain

Book ID: 117569675
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 367 KB
Volume: 24
Category: Article
ISSN: 0748-7983
DOI: 10.1016/s0748-7983(98)91485-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Liver Metastases From Uveal

Treatment of Liver Metastases From Uveal Melanoma

✍ Michel Rivoire; Laurent Kodjikian; Stefano Baldo; Pierre Kaemmerlen; Sylvie Négr 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 115 KB

Prognostic factors of liver metastases f

Prognostic factors of liver metastases from uveal melanoma

✍ Laurent Kodjikian; Jean-Daniel Grange; Stéphano Baldo; Stéphanie Baillif; Justus 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 134 KB

Treatment of liver metastases from uveal

Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis

✍ Yang, Xiao-Yu; Xie, Feng; Tao, Ran; Li, Ai-Jun; Wu, Meng-Chao 📂 Article 📅 2013 🏛 Zhejiang University School of Medicine, China 🌐 English ⚖ 142 KB

Prolonged survival after resection of li

Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy

✍ Laurent Kodjikian; Jean-Daniel Grange; Michel Rivoire 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 114 KB

Long-term survival of uveal melanoma pat

Long-term survival of uveal melanoma patients after surgery for liver metastases

✍ Frenkel, S; Nir, I; Hendler, K; Lotem, M; Eid, A; Jurim, O; Pe'er, J 📂 Article 📅 2009 🏛 BMJ Publishing Group 🌐 English ⚖ 168 KB

Infrequent promoter methylation of the M

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma

✍ Verena Voelter; Annie-Claire Diserens; Alexandre Moulin; Georg Nagel; Pu Yan; Eu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 180 KB

## Abstract Uveal melanoma is associated with a high mortality rate once metastases occur, with over >90% of metastatic patients dying within less than 1 year from metastases to the liver. The intraarterial hepatic (iah) administration of the alkylating agent fotemustine holds some promise with res